miR‐149 and miR‐29c as candidates for bipolar disorder biomarkers

Choi, Jason Lee; Kao, Patricia F.; Itriago, Elena; Zhan, Yougen; Kozubek, James; Hoss, Andrew G.; Banigan, Meredith G.; Vanderburg, Charles R.; Rezvani, Amir H.; Latourelle, Jeanne C.; Cabral, Howard; Delalle, Ivana

doi:10.1002/ajmg.b.32518

Cited by 37 publications

(28 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors of the present study hypothesized an association between BMP-2 and postmenopausal osteoporosis, and miRs that may regulate BMP-2 were investigated in the present study. Previous studies have identified a number of miRs as biomarkers for different diseases (39,40). In the current study, bioinformatics tools were utilized to identify upstream genes predicted to regulate BMP-2, which resulted in the identification of miR-410 as a potential upstream regulator.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein‑2

Zhang

Ding

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

The present study aimed to investigate bone morphogenetic protein (BMP)-2 and microRNA (miR)-410 expression and the mechanism of regulation in serum and CD 14+ peripheral blood mononuclear cells (PBMCs) from postmenopausal osteoporosis patients and model mice. A total of 26 patients with postmenopausal osteoporosis were included in the experimental group and 29 age-matched healthy subjects were included in the control group. A total of 60 mice were divided into sham and ovariectomized (OVX) groups. Following surgery, 28 mice remained in the sham and 25 mice remained in OVX group. BMP-2 protein expression in serum and CD 14+ PBMCs from patients and model mice was determined using ELISA and western blotting, respectively. Reverse transcription-quantitative polymerase chain reaction assays were performed to determine miR-410 and BMP-2 mRNA levels in serum and CD 14+ PBMCs from patients and model mice. Dual luciferase reporter assays were used to identify direct interactions between miR-410 and BMP-2 mRNA. Compared with the control group, BMP-2 mRNA and protein expression in serum and CD 14+ PBMCs from patients with postmenopausal osteoporosis and model mice were significantly decreased. miR-410 levels in serum and CD 14+ PBMCs from patients with postmenopausal osteoporosis and model mice were significantly increased when compared with the control group. Dual luciferase reporter assays revealed that BMP-2 was a target gene of miR-410. The current study demonstrated that decreased BMP-2 expression in serum and CD 14+ PBMCs from patients with postmenopausal osteoporosis was associated with the upregulation of miR-410. These results suggest that miR-410 may participate in the pathological process of postmenopausal osteoporosis by downregulating BMP-2.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‑410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein‑2

Zhang

Ding

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…The histological studies on glial cell loss are supported by the recent molecular findings on altered microRNA (miRNA) levels in the brains of BD patients. For example Choi et al ( 2017 ) extracted extracellular vesicles from the PFC (Brodmann area 24) and found increased levels of miR-149 exclusively in glial cells. Since miR-149 can inhibit glial cell proliferation thus, increased miR-149 expression might contribute to the glial cell number reduction.…”

Section: Cellular Evidences For Glial Pathologymentioning

confidence: 99%

Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders

Czéh

Nagy

2018

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Depressive disorders are complex, multifactorial mental disorders with unknown neurobiology. Numerous theories aim to explain the pathophysiology. According to the “gliocentric theory”, glial abnormalities are responsible for the development of the disease. The aim of this review article is to summarize the rapidly growing number of cellular and molecular evidences indicating disturbed glial functioning in depressive disorders. We focus here exclusively on the clinical studies and present the in vivo neuroimaging findings together with the postmortem molecular and histopathological data. Postmortem studies demonstrate glial cell loss while the in vivo imaging data reveal disturbed glial functioning and altered white matter microstructure. Molecular studies report on altered gene expression of glial specific genes. In sum, the clinical findings provide ample evidences on glial pathology and demonstrate that all major glial cell types are affected. However, we still lack convincing theories explaining how the glial abnormalities develop and how exactly contribute to the emotional and cognitive disturbances. Abnormal astrocytic functioning may lead to disturbed metabolism affecting ion homeostasis and glutamate clearance, which in turn, affect synaptic communication. Abnormal oligodendrocyte functioning may disrupt the connectivity of neuronal networks, while microglial activation indicates neuroinflammatory processes. These cellular changes may relate to each other or they may indicate different endophenotypes. A theory has been put forward that the stress-induced inflammation—mediated by microglial activation—triggers a cascade of events leading to damaged astrocytes and oligodendroglia and consequently to their dysfunctions. The clinical data support the “gliocentric” theory, but future research should clarify whether these glial changes are truly the cause or simply the consequences of this devastating disorder.

show abstract

“…This suggests changes in miRNA may underlie fundamental dysregulated pathways in mood disorders. Recent studies have also highlighted the importance of extracellular vesicles, such as exosomes and microvesicles, in the CNS or in the periphery in individuals with mood disorders, most notably in BD [38][39][40]. Such vesicles can traffic aberrantly expressed miRNA between cells, effectively regulating RNA translation in nearby cells.…”

Section: Micro Rna In Mood Disordersmentioning

confidence: 99%

Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?

Gibbons

Sundram

Dean

2020

ncRNA

View full text Add to dashboard Cite

The similarities between the depressive symptoms of Major Depressive Disorders (MDD) and Bipolar Disorders (BD) suggest these disorders have some commonality in their molecular pathophysiologies, which is not apparent from the risk genes shared between MDD and BD. This is significant, given the growing literature suggesting that changes in non-coding RNA may be important in both MDD and BD, because they are causing dysfunctions in the control of biochemical pathways that are affected in both disorders. Therefore, understanding the changes in non-coding RNA in MDD and BD will lead to a better understanding of how and why these disorders develop. Furthermore, as a significant number of individuals suffering with MDD and BD do not respond to medication, identifying non-coding RNA that are altered by the drugs used to treat these disorders offer the potential to identify biomarkers that could predict medication response. Such biomarkers offer the potential to quickly identify patients who are unlikely to respond to traditional medications so clinicians can refocus treatment strategies to ensure more effective outcomes for the patient. This review will focus on the evidence supporting the involvement of non-coding RNA in MDD and BD and their potential use as biomarkers for treatment response.

show abstract

miR‐149 and miR‐29c as candidates for bipolar disorder biomarkers

Cited by 37 publications

References 57 publications

MicroRNA‑410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein‑2

MicroRNA‑410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein‑2

Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders

Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?

Contact Info

Product

Resources

About